NAS:NITE (UK)

Nightstar Therapeutics PLC

$ 25.41 0 (0%)
Volume: 0 Avg Vol (1m): 151,964
Market Cap $: 852.16 Mil Enterprise Value $: 698.70 Mil
P/E (TTM): 0.00 P/B: 5.59
Earnings Power Value 0
Net Current Asset Value 4.49
Tangible Book 4.55
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
N/A
Interest Coverage No Debt
N/A
Altman Z-Score 24.88
DISTRESS
GREY
SAFE

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -30.26
ROE range over the past 10 years
Min: -122.93, Med: -82.57, Max: -25.3
Current: -30.26
-122.93
-25.3
ROA % -27.23
ROA range over the past 10 years
Min: -96.99, Med: -62.37, Max: -23.39
Current: -27.23
-96.99
-23.39
ROC (Joel Greenblatt) % -11626.67
ROC (Joel Greenblatt) range over the past 10 years
Min: -11626.67, Med: -5814.27, Max: -3685.38
Current: -11626.67
-11626.67
-3685.38
3-Year Total EBITDA Growth Rate -67.80
N/A

» NITE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-13)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NITE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2836
Compare NAS:SYRS NAS:ADVM XSWX:SKIN XPAR:IPH SHSE:603229 SZSE:002868 NAS:CARA NAS:MRSN WAR:CLN TSXV:EMH LSE:CIR NAS:IDRA NAS:CORI XTER:MDG1 OTCPK:RCAR LSE:ARIX NAS:PIRS NAS:SNNA OSTO:ONCO NAS:KALA
Traded in other countries
Address 215 Euston Road, London, GBR, NW1 2BE
Nightstar Therapeutics Ltd is a clinical-stage gene therapy company. It is focused on developing and commercializing a pipeline of novel and potentially curative, one-time retinal gene therapies for patients suffering from rare inherited retinal diseases. The company's retinal gene therapy product candidate, NSR-REP1, is being developed for the treatment of choroideremia, a rare, degenerative, X-linked genetic retinal disorder primarily affecting males that is caused by a mutation in the CHM gene.

Ratios

Current vs industry vs history
PB Ratio 5.59
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 7.51
Current: 5.59
0
7.51
EV-to-EBIT -12.97
EV-to-EBIT range over the past 10 years
Min: -25.69, Med: 0, Max: 0
Current: -12.97
-25.69
0
EV-to-EBITDA -13.04
EV-to-EBITDA range over the past 10 years
Min: -25.87, Med: 0, Max: 0
Current: -13.04
-25.87
0
Current Ratio 8.54
Current Ratio range over the past 10 years
Min: 2.56, Med: 8.54, Max: 14.37
Current: 8.54
2.56
14.37
Quick Ratio 8.54
Quick Ratio range over the past 10 years
Min: 2.56, Med: 8.54, Max: 14.37
Current: 8.54
2.56
14.37

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -35.60
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 5.58
Price-to-Tangible-Book range over the past 10 years
Min: 2.28, Med: 3.87, Max: 5.92
Current: 5.58
2.28
5.92
Earnings Yield (Joel Greenblatt) % -7.71
Earnings Yield (Greenblatt) range over the past 10 years
Min: -17.61, Med: 0, Max: 0
Current: -7.71
-17.61
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N